Neutralizing antibodies for the prevention and treatment of COVID-19

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus-cell memb...

Full description

Saved in:

Bibliographic Details
Published in:	Cellular & molecular immunology Vol. 18; no. 10; pp. 2293 - 2306
Main Authors:	Du, Lanying, Yang, Yang, Zhang, Xiujuan
Format:	Journal Article
Language:	English
Published:	China Nature Publishing Group 01.10.2021
Subjects:	ACE2 Angiotensin Angiotensin-converting enzyme 2 Animals Antibodies, Monoclonal, Humanized - chemistry Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Neutralizing - chemistry Antibodies, Neutralizing - therapeutic use Antibodies, Viral - chemistry Antibodies, Viral - therapeutic use Cell fusion Cell membranes Clinical Trials as Topic Coronaviruses COVID-19 COVID-19 Drug Treatment Drug Approval Drug Combinations Humans Membrane fusion Monoclonal antibodies Peptidyl-dipeptidase A Proteins SARS-CoV-2 - chemistry Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - chemistry Therapeutic targets COVID-19 Monoclonal antibodies SARS-CoV-2 Spike protein Neutralization
ISSN:	1672-7681, 2042-0226, 2042-0226
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!